Liver Transplant Program, Cleveland Clinic, Cleveland, OH, USA.
Transpl Int. 2013 Jan;26(1):11-9. doi: 10.1111/j.1432-2277.2012.01550.x. Epub 2012 Sep 2.
Living donor liver transplantation (LDLT) is a well-established strategy to decrease the mortality in the waiting list and recent studies have demonstrated its value even in patients with low MELD score. However, LDLT is still under a high level of scrutiny because of its technical complexity and ethical challenges as demonstrated by a decline in the number of procedures performed in the last decade in Western Countries. Many aspects make LDLT different from deceased donor liver transplantation, including timing of transplantation, procedure-related complications as well as immunological factors that may affect graft outcomes. Our review suggests that in selected cases, LDLT offers significant advantages over deceased donor liver transplantation and should be used more liberally.
活体肝移植（LDLT）是降低等待名单死亡率的成熟策略，最近的研究表明，即使在 MELD 评分较低的患者中，它也具有价值。然而，由于其技术复杂性和伦理挑战，LDLT 仍受到高度关注，这表现在过去十年中西方国家进行的手术数量有所下降。许多方面使 LDLT 与已故供体肝移植不同，包括移植时机、与手术相关的并发症以及可能影响移植物结局的免疫因素。我们的综述表明，在选定的情况下，LDLT 比已故供体肝移植具有显著优势，应该更自由地使用。
